AstraZeneca has unveiled an at-home delivery option for its FluMist nasal spray flu vaccine, allowing parents to vaccinate their children without leaving home. This groundbreaking move aims to boost vaccination rates amid declining flu shot coverage.
AstraZeneca's FluMist Home, a nasal flu vaccine available for at-home use, aims to improve vaccination rates among children, especially those afraid of needles. Experts discuss its effectiveness and accessibility.
In a controversial move, a vaccine advisory panel recommends removing thimerosal from flu vaccines despite studies showing its benefits. Discover the implications for public health and vaccine safety.
Robert F. Kennedy Jr. canceled a critical $766 million contract with Moderna for a bird flu vaccine, raising concerns about public health and vaccine safety amidst a potential outbreak.
The U.S. government has canceled a crucial $770 million contract with Moderna for an avian flu vaccine, risking public health as pandemics prove to be a costly threat. Experts warn of the implications of prioritizing military spending over health security.
In a surprising move, the Department of Health and Human Services has withdrawn millions in funding for Moderna's bird flu vaccine development, raising concerns about the nation's pandemic preparedness amid ongoing tensions over vaccine safety.
Vaccine experts are divided over the Trump administration's Generation Gold Standard project aimed at creating a universal flu vaccine. While some praise the initiative, others question its outdated methods and hefty price tag.
Moderna's combined Covid and flu vaccine has outperformed traditional shots in a recent phase 3 trial, generating higher antibody levels and showing promise for dual protection against both viruses.
The announcement of a $500 million NIH project to develop a vaccine platform using outdated technology has divided experts, sparking concerns about the future of pandemic preparedness and funding priorities.
The U.S. Department of Health and Human Services is on a bold mission to develop a universal flu vaccine within four years, a project that could revolutionize how we combat influenza and prepare for future pandemics. Funded by $500 million, this initiative aims for FDA approval by 2029, with clinical trials starting soon. Experts weigh in on the challenges and potential of this ambitious project.
